Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment option for patients with relapsed/refractory large B-cell lymphoma. However, widespread use is deterred by the development of clinically significant acute inflammatory toxicities, including cytokine release synd...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalota, Akansha, Hershberger, Courtney E., Patel, Manishkumar S., Mian, Agrima, Faruqi, Aiman, Khademi, Gholamreza, Rotroff, Daniel M., Hill, Brian T., Gupta, Neetu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468366/
https://www.ncbi.nlm.nih.gov/pubmed/36399526
http://dx.doi.org/10.1182/bloodadvances.2022007456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468366/
https://www.ncbi.nlm.nih.gov/pubmed/36399526
http://dx.doi.org/10.1182/bloodadvances.2022007456

Ejemplares similares